Allison Derenne (General manager) holds a Bachelor and a Master in Bioengineering from the Université libre de Bruxelles (ULB). She also obtained a Ph.D. in Sciences from the Laboratory of Structure and Function of Biological Membranes of the ULB (supervisor: Porf. Erik Goormaghtigh). During her thesis, she developed a method based on FTIR spectroscopy to classify anticancer agents according to their mode of action using the cell biochemical modifications induced by the drug. Her research has been the subject of 10+ scientific articles (7 as first author) published in international journals.
Since 2013, based on her acquired knowledge about the technology, she is working on designing innovative methods for the industry to analyze therapeutic proteins using FTIR spectroscopy. Allison has been nominated among the 2016 Under 35 Belgian Young Innovators by the Massachusetts Institute for Technology (MIT) and has participated in numerous international conferences, for which she twice received the price for best poster presentation.
She founded Spectralys Biotech in October 2018. One current project consists of developing a method based on FTIR spectroscopy to evaluate protein glycosylation (quantity and nature). Another project running is the development of FTIR-based biosensors.